Stroke remains a leading cause of death and disability in Europe. However substantial progress has recently been made in thrombolytic therapy and in 1996t-PA became the first FDA approved interventional treatment for acute ischaemicstroke. T-PA therapy MUST take place within three hours of the onset of symptoms. Thus, traditional methods of diagnosis, such as MRI and CT are not practical. Recently a panel of biochemical markers have been introduced as early markers of stroke; i.e. neuron specific enlace, myelin basic protein, S-100b andthrombomodulin. These markers are laboratory tests and are time consuming in situation when time is of grave importance. The aim of this project is to develop highly novel labels immunosensors for the rapid and cost effective detection of these markers, facilitating the early diagnosis of stroke essential for introduction of thrombolytic therapy, thus preventing disability and stroke mortality, a move of vast socio-economic importance.
Funding SchemeEAW - Exploratory awards
3526 KL Utrecht